ESC Premium Access

What proportion of patients with heart failure are candidates for sacubitril/valsartan? Differences between guideline recommendations and regulatory labels

Presentation

About the speaker

Doctor Pierpaolo Pellicori

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)
1 presentation
0 follower

8 more presentations in this session

Hemodynamic evaluation of patients with advanced heart failure receiving ambulatory intermittent cycles of levosimendan as bridge to transplant

Speaker: Doctor I. Hernandez Gonzalez (Valladolid, ES)

Thumbnail

Cardiorenal protection by subcutaneous cenderitide in experimental heart failure: a novel and safe therapeutic for humans with LVAD support

Speaker: Doctor T. Ichiki (Rochester, US)

Thumbnail

Identification of patients eligible to start sacubitril valsartan in a stable heart failure population

Speaker: Doctor S. Aktaa (Leeds, GB)

Thumbnail

Initiation of sacubitril/valsartan in hospitalized patients with HFrEF after hemodynamic stabilization: baseline characteristics of the TRANSITION study compared with TITRATION and PARADIGM-HF

Speaker: Doctor M. Senni (Bergamo, IT)

Thumbnail

Oral donepezil markedly suppresses the progression of cardiovascular remodeling and improves the prognosis in spontaneously hypertensive rats with myocardial infarction

Speaker: Doctor M. Li (Osaka, JP)

Thumbnail

Access the full session

Poster Session 7 - Chronic heart failure – Treatment

Speakers: Doctor P. Pellicori, Doctor I. Hernandez Gonzalez, Doctor T. Ichiki, Doctor S. Aktaa, Doctor M. Senni...
Thumbnail

About the event

Image

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

This platform is supported by

logo Novo Nordisk